Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2008 financial results after the NASDAQ Global Market closes on Tuesday, August 5, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the second quarter 2008 financial results and to provide a corporate update.

The conference call may be accessed by dialing 877.419.6590 for domestic callers and 719.325.4872 for international callers. Please specify to the operator that you would like to join the "Arena Second Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independentl
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... MUMBAI, India , June 26, 2015 ... a leading global IT services, consulting and business solutions ... Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by ... MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor ... The report evaluated eight leading IT services vendors with ...
(Date:6/26/2015)... ... June 26, 2015 , ... ReliantHeart, Inc. , an innovative supplier of ... implant of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, there has been ... originates in an LVAD is referred to as de novo thrombus. De novo thrombus ...
(Date:6/25/2015)... ... 2015 , ... Students entering the new Hemenway Hall addition ... exclusively using filtered fume hoods that feature Erlab’s GreenFumeHood Filtration Technology . ... needed for their Organic, Inorganic, Analytical, and Physical Chemistry teaching laboratories. Each filtered ...
(Date:6/25/2015)... , June 25, 2015 /PRNewswire/ - Portage Biotech ... , OTC Markets : PTGEF,), is pleased to announce ... US$5,155,080 through issuance of approximately 36.8 million common shares ... two tranches, first tranche closed on June 15, 2015 ... and second and final tranche closed on June 24, ...
Breaking Biology Technology:TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080 2Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080 3
... 5, 2012  PharmAthene, Inc. (NYSE Amex: PIP ), ... threats, announced today that management will present at the ROTH ... 2012 at 5:30 pm PT at the Ritz-Carlton Laguna Niguel ... ConferenceDate : , Monday, March 12, 2012 at 5:30 pm ...
... difference between salt water and fresh water is most ... bicarbonate salt solution, Penn State researchers can combine bacterial ... salt-water fresh-water gradient to produce power anywhere. "We ... them together," said Bruce E. Logan, Kappe Professor of ...
... -- FirstMark, the diagnostic division of GenWay Biotech, announced ... was held today on March 1, 2012. The Board ... research. The main focus of the Board will be ... of FirstMark,s new cardiovascular test PREvent. PREvent is the ...
Cached Biology Technology:Unique salt allows energy production to move inland 2Inaugural Meeting of the FirstMark Scientific Board of Advisors 2Inaugural Meeting of the FirstMark Scientific Board of Advisors 3
(Date:6/8/2015)... SAN DIEGO , June 8, 2015  Trovagene, Inc. ... announced today that clinical data featuring its Precision Cancer Monitoring ... Cancer Markers and Liquid Biopsies conference in San ... the AACR Precision Medicine Series: Integrating Clinical Genomics and ... on June 13-16. "We continue ...
(Date:6/5/2015)... GERMANTOWN, Md. , June 5, 2015  Intrexon ... synthetic biology, today announced that it has determined the ... of all of its 17,830,305 shares of ZIOPHARM Oncology, ... or about June 12, 2015, the distribution date, as ... stock, and on warrants to purchase shares of Intrexon ...
(Date:6/1/2015)... -- According to a new market research ... (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & Others), ... Global Forecast to 2020", published by MarketsandMarkets, the Gesture ... $23.55 Billion by 2020, at a CAGR of 28.23% ... market data T ables and   86   ...
Breaking Biology News(10 mins):Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4
... liver disease, extent of tissue damage depends on the balance ... new liver cells. In a significant minority of people who ... form scars. This can progress to chronic liver disease and ... unable to clean blood or produce vital hormones and clotting ...
... a type of cell that can be activated by tissues ... attack our own molecules, cells and organs, UCSF researchers have ... new strategies for fighting a range of autoimmune diseases ... and cells within us as well as for preventing ...
... CHICAGO A low-calorie diet eliminates insulin dependence ... with type 2 diabetes, according to a study presented ... of North America (RSNA). "Lifestyle interventions may have ... patients," said the study,s lead author, Sebastiaan Hammer, M.D., ...
Cached Biology News:The immune system has protective memory cells, researchers discover 2The immune system has protective memory cells, researchers discover 3Restricted calorie diet improves heart function in obese patients with diabetes 2
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... Human IgM Assay Kit to address the ... assay for Human IgM that eliminates the ... a simple mix-and-read assay that allows the ... ng/ml in approximately 30 minutes. The Pierce ...
AC input: 230 V...
Biology Products: